Logo image of ROIV

ROIVANT SCIENCES LTD (ROIV) Stock Price, Quote, News and Overview

NASDAQ:ROIV - Nasdaq - BMG762791017 - Common Stock - Currency: USD

11.55  +0.17 (+1.49%)

After market: 11.55 0 (0%)

ROIV Quote, Performance and Key Statistics

ROIVANT SCIENCES LTD

NASDAQ:ROIV (7/25/2025, 8:23:08 PM)

After market: 11.55 0 (0%)

11.55

+0.17 (+1.49%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.06
52 Week Low8.73
Market Cap7.85B
Shares679.81M
Float399.33M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-03 2020-12-03


ROIV short term performance overview.The bars show the price performance of ROIV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 1 2 3 4

ROIV long term performance overview.The bars show the price performance of ROIV in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100 150

The current stock price of ROIV is 11.55 USD. In the past month the price decreased by -0.43%. In the past year, price increased by 6.94%.

ROIVANT SCIENCES LTD / ROIV Daily stock chart

ROIV Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.53 336.11B
AMGN AMGEN INC 14.77 164.85B
GILD GILEAD SCIENCES INC 15.01 144.54B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.61B
REGN REGENERON PHARMACEUTICALS 12.71 60.80B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.87B
ARGX ARGENX SE - ADR 103.13 36.23B
ONC BEONE MEDICINES LTD-ADR 7.44 31.54B
BNTX BIONTECH SE-ADR N/A 27.72B
SMMT SUMMIT THERAPEUTICS INC N/A 21.29B
INSM INSMED INC N/A 19.72B
BIIB BIOGEN INC 8.31 19.27B

About ROIV

Company Profile

ROIV logo image Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.

Company Info

ROIVANT SCIENCES LTD

11-12 St. James's Square, Suite 1, 3rd Floor

London GB

Employees: 908

ROIV Company Website

ROIV Investor Relations

Phone: 442074003347.0

ROIVANT SCIENCES LTD / ROIV FAQ

What is the stock price of ROIVANT SCIENCES LTD today?

The current stock price of ROIV is 11.55 USD. The price increased by 1.49% in the last trading session.


What is the ticker symbol for ROIVANT SCIENCES LTD stock?

The exchange symbol of ROIVANT SCIENCES LTD is ROIV and it is listed on the Nasdaq exchange.


On which exchange is ROIV stock listed?

ROIV stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ROIVANT SCIENCES LTD stock?

16 analysts have analysed ROIV and the average price target is 19.76 USD. This implies a price increase of 71.1% is expected in the next year compared to the current price of 11.55. Check the ROIVANT SCIENCES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ROIVANT SCIENCES LTD worth?

ROIVANT SCIENCES LTD (ROIV) has a market capitalization of 7.85B USD. This makes ROIV a Mid Cap stock.


How many employees does ROIVANT SCIENCES LTD have?

ROIVANT SCIENCES LTD (ROIV) currently has 908 employees.


What are the support and resistance levels for ROIVANT SCIENCES LTD (ROIV) stock?

ROIVANT SCIENCES LTD (ROIV) has a support level at 11.49 and a resistance level at 11.61. Check the full technical report for a detailed analysis of ROIV support and resistance levels.


Is ROIVANT SCIENCES LTD (ROIV) expected to grow?

The Revenue of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -68.82% in the next year. Check the estimates tab for more information on the ROIV EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ROIVANT SCIENCES LTD (ROIV) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ROIVANT SCIENCES LTD (ROIV) stock pay dividends?

ROIV does not pay a dividend.


What is the Price/Earnings (PE) ratio of ROIVANT SCIENCES LTD (ROIV)?

ROIVANT SCIENCES LTD (ROIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).


What is the Short Interest ratio of ROIVANT SCIENCES LTD (ROIV) stock?

The outstanding short interest for ROIVANT SCIENCES LTD (ROIV) is 10.29% of its float. Check the ownership tab for more information on the ROIV short interest.


ROIV Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ROIV. When comparing the yearly performance of all stocks, ROIV turns out to be only a medium performer in the overall market: it outperformed 51.39% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ROIV Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ROIV. ROIV has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ROIV Financial Highlights

Over the last trailing twelve months ROIV reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 80.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -3.16%
ROE -3.67%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-52.63%
Sales Q2Q%-73.83%
EPS 1Y (TTM)80.31%
Revenue 1Y (TTM)-76.72%

ROIV Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ROIV. The Buy consensus is the average rating of analysts ratings from 16 analysts.

For the next year, analysts expect an EPS growth of -426.32% and a revenue growth -68.82% for ROIV


Ownership
Inst Owners72.54%
Ins Owners7.75%
Short Float %10.29%
Short Ratio6.47
Analysts
Analysts85
Price Target19.76 (71.08%)
EPS Next Y-426.32%
Revenue Next Year-68.82%